Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation

Oligomeric assemblies of neurotoxic amyloid beta (Abeta) peptides generated by proteolytical processing of the amyloid precursor protein (APP) play a key role in the pathogenesis of Alzheimer’s disease (AD). In recent years, a substantial heterogeneity of Abeta peptides with distinct bioph...

Full description

Bibliographic Details
Main Authors:	Maike Hartlage-Rübsamen, Alexandra Bluhm, Anke Piechotta, Miriam Linnert, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Inge Lues, Peer-Hendrik Kuhn, Stefan F. Lichtenthaler, Steffen Roßner, Corinna Höfling
Format:	Article
Language:	English
Published:	MDPI AG 2018-04-01
Series:	Molecules
Subjects:	Alzheimer’s disease animal model human APP expression glutaminyl cyclase pyroglutamate-Abeta
Online Access:	http://www.mdpi.com/1420-3049/23/4/924

Similar Items

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
by: Daoyuan Chen, et al.
Published: (2023-08-01)

Tetrahydroimidazo[4,5-<i>c</i>]pyridine-Based Inhibitors of <i>Porphyromonas gingivalis</i> Glutaminyl Cyclase
by: Daniel Ramsbeck, et al.
Published: (2021-11-01)

Functions of glutaminyl cyclase and its isoform in diseases
by: Liu Yu’e, et al.
Published: (2023-01-01)

The Bacteroidetes Q-Rule: Pyroglutamate in Signal Peptidase I Substrates
by: Matthias Bochtler, et al.
Published: (2018-03-01)

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors
by: Stephanie Hielscher-Michael, et al.
Published: (2016-11-01)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
by: Dr. Chenshu Xu, et al.
Published: (2021-09-01)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
by: Philip Scheltens, et al.
Published: (2018-10-01)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
by: Claire Bridel, et al.
Published: (2017-06-01)

Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
by: Torsten Hoffmann, et al.
Published: (2021-10-01)

Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer’s Disease and Its Tg2576 Mouse Model
by: Alexandra Bluhm, et al.
Published: (2022-07-01)

Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death
by: H. Lison, et al.
Published: (2014-03-01)

Design, Synthesis, and Validation of a Novel [<sup>11</sup>C]Promethazine PET Probe for Imaging Abeta Using Autoradiography
by: Clayton A. Whitmore, et al.
Published: (2021-04-01)

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD
by: E. G. B. Vijverberg, et al.
Published: (2021-08-01)

Acute Effects of Focused Ultrasound-Induced Blood-Brain Barrier Opening on Anti-Pyroglu3 Abeta Antibody Delivery and Immune Responses
by: Praveen Bathini, et al.
Published: (2022-07-01)

Acute Blast Injury Reduces Brain Abeta in Two Rodent Species
by: Rita eDe Gasperi, et al.
Published: (2012-12-01)

White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review
by: Frank R. Sharp, et al.
Published: (2023-02-01)

Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer’s disease
by: Maike Hartlage-Rübsamen, et al.
Published: (2019-05-01)

Changes of Adenylate Cyclase and Guanylate Cyclase in the Frontal Cortex, Lenticula, Corpus Amygdaloideum, and Hippocampus in Morphine-dependent Rats
by: Shijun Hong, et al.
Published: (2016-01-01)

Cellular response to β‐amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics
by: Haolin Zhang, et al.
Published: (2023-02-01)

Soluble variants of human recombinant glutaminyl cyclase.
by: Cristiana Castaldo, et al.
Published: (2013-01-01)

Opposite changes in APP processing and human Aβ levels in rats carrying either a protective or a pathogenic APP mutation
by: Marc D Tambini, et al.
Published: (2020-02-01)

Editorial: Adenylyl cyclase isoforms as potential drug targets
by: Tarsis F. Brust, et al.
Published: (2022-12-01)

Synthesis of New Optically Active 2-Pyrrolidinones
by: Thomas Mavromoustakos, et al.
Published: (2012-12-01)

Optogenetic manipulation of neuronal and cardiomyocyte functions in zebrafish using microbial rhodopsins and adenylyl cyclases
by: Hanako Hagio, et al.
Published: (2023-08-01)

Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases
by: Qinan Yin, et al.
Published: (2023-12-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

The Roles of Lipid and Glucose Metabolism in Modulation of β-Amyloid, Tau, and Neurodegeneration in the Pathogenesis of Alzheimer disease
by: Naoyuki eSato, et al.
Published: (2015-10-01)

ApoE transiently regulates hippocampus amyloid‐beta deposition to stable learning and memory ability in adult rats exposed in sevoflurane
by: Shan Xu, et al.
Published: (2021-06-01)

Abstract P-34: The Regulation of Amyloid Proteins Aggregation by Adjacent Domains
by: Anastasia V. Grizel, et al.
Published: (2019-06-01)

Cell Type-Specific Human APP Transgene Expression by Hippocampal Interneurons in the Tg2576 Mouse Model of Alzheimer’s Disease
by: Corinna Höfling, et al.
Published: (2019-02-01)

Research Advances in Oxidosqualene Cyclase in Plants
by: Pengqing Wang, et al.
Published: (2022-08-01)

Age Impairs Soluble Guanylyl Cyclase Function in Mouse Mesenteric Arteries
by: Cheng Zhong, et al.
Published: (2021-10-01)

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
by: Helen Crehan, et al.
Published: (2020-01-01)

Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation
by: Schmidt Kurt, et al.
Published: (2013-06-01)

Bordetella Adenylate Cyclase-Hemolysin Toxins
by: Nicole Guiso
Published: (2017-09-01)

Possible Modification of Alzheimer Disease by Statins in Midlife: Interactions with Genetic and Non-Genetic Risk Factors
by: Mitsuru eShinohara, et al.
Published: (2014-04-01)

Interaction Of GCAP1 With Retinal Guanylyl Cyclase And Calcium: Sensitivity to Fatty Acylation
by: Igor V. Peshenko, et al.
Published: (2012-02-01)

ADENYLYL CYCLASE ASSAYS TO MEASURE MACROPHAGE CHEMOTACTIC PROTEIN-1 RECEPTOR FUNCTION
by: Durdi Qujeq, et al.
Published: (2000-04-01)

Structural basis of retinal membrane guanylate cyclase regulation by GCAP1 and RD3
by: James B. Ames
Published: (2022-09-01)

Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure∗
by: J. David Port, PhD, et al.
Published: (2016-12-01)